A Dose Range Finding Study of JNJ-39758979 in Patients With Active Rheumatoid Arthritis Currently Treated With Methotrexate
Status:
Withdrawn
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the efficacy, safety and tolerability of JNJ-39758979
at doses of 10, 30, 100, and 300 mg/day compared with placebo (inactive medical substance) in
patients with active rheumatoid arthritis despite concomitant treatment with methotrexate
(MTX).